MK-677 (Ibutamoren)

MK-677 (Ibutamoren mesylate) is a small-molecule, non-peptide ghrelin receptor agonist and growth hormone secretagogue (GHS) originally developed by Reverse Pharmacology and subsequently investigated by Eli Lilly and Merck in clinical trials during the 1990s and 2000s. Despite its name appearing in peptide research circles, it is technically a peptidomimetic — it mimics the action of ghrelin at the GHS-R1a receptor but is structurally a small molecule, granting it oral bioavailability that distinguishes it from injectable GHRPs like GHRP-6 or Ipamorelin. It belongs to the broader class of growth hormone secretagogues and is often researched alongside them despite its distinct chemical identity.

MK-677's primary mechanism involves agonism of the ghrelin receptor (GHS-R1a), which stimulates pituitary release of growth hormone in a pulsatile, physiologically patterned fashion. Critically, published research indicates it does not suppress endogenous GH secretion or cause negative feedback on the hypothalamic-pituitary axis in the way that exogenous recombinant HGH (rhGH) administration does. It also reliably elevates IGF-1 levels, which is the primary downstream mediator of many GH-associated anabolic and regenerative effects. Because it mimics ghrelin, it also stimulates appetite — an effect consistently documented in human trials and relevant for both its research applications in cachexia/wasting conditions and its reported side-effect profile in other contexts.

The evidence base for MK-677 is notably stronger than most compounds in the research-chemical category. Human trials include a double-blind, placebo-controlled crossover study (Svensson et al., 1998, n=24) demonstrating significant GH and IGF-1 elevation, and a landmark two-year randomized controlled trial in elderly subjects (Chapman et al., 1996; Nass et al., 2008) examining effects on body composition, bone density, and functional outcomes. A 2008 trial published in the Annals of Internal Medicine (n=65) found that MK-677 increased lean body mass in elderly subjects over 12 months but did not improve functional outcomes as measured. A separate trial (Copinschi et al., 1996) documented its effects on sleep architecture, with research suggesting increased REM and slow-wave sleep duration. Animal models additionally demonstrate neuroprotective and memory-relevant effects, though these have not been replicated at scale in human trials. Anecdotal user reports in biohacking communities frequently describe improvements in sleep quality, appetite stimulation, and body composition changes — but these are self-reported and uncontrolled and should not be conflated with clinical evidence.

Dosing ranges reported in published human research have varied between 10 mg and 25 mg administered orally once daily. Some trials used doses as low as 2 mg to characterize pharmacokinetics. The 25 mg daily dose is the most commonly referenced in body composition and GH-secretion studies. IMPORTANT: These figures are reported strictly from research contexts and are not a recommendation for human use. MK-677 is not approved for human consumption in any major regulatory jurisdiction, and any dosing information presented here is for educational and research-literacy purposes only.

From a legal and sourcing standpoint, MK-677 occupies an ambiguous position. In the United States, it is unscheduled under the Controlled Substances Act but is also not FDA-approved, placing it in a gray-zone research-chemical category. It has been explicitly added to WADA's prohibited list, making it banned for competitive athletes. In Australia, it falls under Schedule 4 (prescription-only) in some interpretations, and regulatory enforcement has tightened significantly in recent years. In the UK, supply for human use may engage the Medicines Act, though it is not a controlled substance under the Misuse of Drugs Act. Credible vendors should provide third-party COAs confirming identity, purity (HPLC ≥98%), and absence of heavy metals or residual solvents. Because MK-677 is an oral compound, tablet and capsule formulations are common — this makes vendor quality particularly important, as underdosed or adulterated oral products are harder to detect without independent testing. This content is for educational purposes only and does not constitute medical advice.